Fortress Biotech (FBIO) Competitors

XOMA Royalty (NASDAQ:XOMA) and Fortress Biotech (NASDAQ:FBIO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

Is XOMA or FBIO more profitable?

Fortress Biotech has a net margin of -24.84% compared to XOMA Royalty's net margin of -27.57%. XOMA Royalty's return on equity of 2.63% beat Fortress Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XOMA Royalty	-27.57%	2.63%	0.97%
Fortress Biotech	-24.84%	-301.81%	-27.48%

Do institutionals & insiders have more ownership in XOMA or FBIO?

95.9% of XOMA Royalty shares are owned by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are owned by institutional investors. 9.1% of XOMA Royalty shares are owned by insiders. Comparatively, 27.9% of Fortress Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Does the media prefer XOMA or FBIO?

In the previous week, XOMA Royalty had 4 more articles in the media than Fortress Biotech. MarketBeat recorded 5 mentions for XOMA Royalty and 1 mentions for Fortress Biotech. XOMA Royalty's average media sentiment score of 0.77 beat Fortress Biotech's score of 0.59 indicating that XOMA Royalty is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
XOMA Royalty	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fortress Biotech	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts prefer XOMA or FBIO?

XOMA Royalty presently has a consensus price target of $69.50, indicating a potential upside of 89.37%. Fortress Biotech has a consensus price target of $16.50, indicating a potential upside of 349.59%. Given Fortress Biotech's higher probable upside, analysts clearly believe Fortress Biotech is more favorable than XOMA Royalty.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XOMA Royalty	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33
Fortress Biotech	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has higher earnings & valuation, XOMA or FBIO?

XOMA Royalty has higher earnings, but lower revenue than Fortress Biotech. XOMA Royalty is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XOMA Royalty	$28.49M	15.57	-$13.82M	-$1.55	-23.68
Fortress Biotech	$57.67M	1.89	-$46M	-$1.05	-3.50

Which has more risk & volatility, XOMA or FBIO?

XOMA Royalty has a beta of 0.99, indicating that its stock price is 1% less volatile than the S&P 500. Comparatively, Fortress Biotech has a beta of 1.61, indicating that its stock price is 61% more volatile than the S&P 500.

Summary

XOMA Royalty and Fortress Biotech tied by winning 8 of the 16 factors compared between the two stocks.